Used in research and development for studying metabolic disorders, kidney disease, and aging-related conditions. Binds specifically to the Klotho beta protein, enabling investigation of FGF21 signaling pathways involved in glucose and lipid metabolism. Supports target validation in preclinical studies for potential therapeutics in type 2 diabetes, NASH, and other metabolic diseases. Employed in immunoassays and immunohistochemistry to detect and quantify Klotho beta expression in tissues and cell-based models. Also utilized as a neutralizing agent to block Klotho beta function in vitro and in vivo, helping elucidate its biological role.